This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US Federal Circuit suspicious of Teva arguments in Orange Book patent delisting case

By Nick Robertson ( November 8, 2024, 22:53 GMT | Insight) -- Teva Pharmaceuticals argued in front of the US Court of Appeals for the Federal Circuit that its inhaler patents should remain in the FDA's "Orange Book" despite not having explicit reference to its active ingredient, in a case that could carry implications for future Hatch-Waxman disputes and which has drawn significant attention from major pharmaceutical companies and regulators.A three-judge panel of the US Court of Appeals for the Federal Circuit appeared suspicious of Teva Pharmaceuticals' claims in oral arguments today in a case against Amneal Pharmaceuticals — claims that attempt to halt the delisting of a group of FDA “Orange Book” patents for Teva's inhaler product....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections